Cargando…

The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study

BACKGROUND: The aim of this study was to investigate the optimal order of radiation therapy in patients affected by stage IIIA pathologic N2 (IIIA/N2) non-small-cell lung cancer (NSCLC) and to identify its potential risk factors. METHODS: 17,654 (8786 men and 8868 women) diagnosed with NSCLC stage I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duan, Hongxia, Liang, Long, Xie, Shuanshuan, Wang, Changhui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448510/ https://www.ncbi.nlm.nih.gov/pubmed/32847544 http://dx.doi.org/10.1186/s12885-020-07309-y

Ejemplares similares

The Valuable Prognostic Impact of Regional Lymph Node Removed on Outcomes for IIIA N0 NSCLC Patients
por: Wang, Yukun, et al.
Publicado: (2023)

Exploration of the optimal number of regional lymph nodes removed for resected N0 NSCLC patients: A population-based study
por: Yao, Anjie, et al.
Publicado: (2022)

PARC/CCL18 is Associated with Inflammation, Emphysema Severity and Application of Inhaled Corticosteroids in Hospitalized COPD Patients
por: Duan, Hongxia, et al.
Publicado: (2021)

Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations
por: Marchetti, Antonio, et al.
Publicado: (2022)

Robotic-assisted thoracoscopic surgery for clinically stage IIIA (c-N2) NSCLC—is it justified?
por: Weder, Walter, et al.
Publicado: (2021)

Phosphorylation of CAP1 regulates lung cancer proliferation, migration, and invasion
por: Zeng, Jie, et al.
Publicado: (2021)

Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC
por: Zhang, Haoran, et al.
Publicado: (2023)

Value of transbronchial needle aspiration combined with a rapid on-site evaluation of cytology in the diagnosis of pulmonary lesions
por: Liang, Long, et al.
Publicado: (2022)

Safety, feasibility, and effectiveness of a novel spray cryotherapy technique in a canine model
por: Duan, Hongxia, et al.
Publicado: (2021)

Adjuvant chemotherapy is not a decisive factor in improving the overall survival of pulmonary sarcoma: A population-based study
por: Liang, Long, et al.
Publicado: (2022)

Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers
por: Kilvaer, Thomas K., et al.
Publicado: (2015)

Neoadjuvant chemoimmunotherapy as a potential therapeutic option in NSCLC UICC stage IIIA with multilevel N2 disease
por: Menghesha, Hruy, et al.
Publicado: (2022)

Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number
por: Wang, Siwei, et al.
Publicado: (2017)

Effects of postoperative radiotherapy on cardiovascular-pulmonary disease mortality in patients with stage IIIA-N2 resected NSCLC: analysis of the SEER database
por: Wang, Xia, et al.
Publicado: (2021)

Lymph node volume predicts survival but not nodal clearance in Stage IIIA-IIIB NSCLC
por: Agrawal, Vishesh, et al.
Publicado: (2017)

Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA
por: Wallerek, Sandra, et al.
Publicado: (2015)

Preliminary Results of Robotic Lobectomy in Stage IIIA-N2 NSCLC after Induction Treatment: A Case Control Study
por: Casiraghi, Monica, et al.
Publicado: (2021)

Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity
por: Dan, Aravot, et al.
Publicado: (2019)

Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I–IIIA NSCLC
por: Garitaonaindia, Yago, et al.
Publicado: (2023)

The Clinical Characteristics and Treatments for Large Cell Carcinoma Patients Older than 65 Years Old: A Population-Based Study
por: Yao, Anjie, et al.
Publicado: (2022)

Role of surgery in patients with early stage small-cell lung cancer
por: Peng, Aimei, et al.
Publicado: (2019)

Resectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment
por: Brascia, Debora, et al.
Publicado: (2020)

Correction to: Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity
por: Aravot, Dan, et al.
Publicado: (2019)

Postoperative radiotherapy for pathological stage IIIA‐N2 non‐small cell lung cancer with positive surgical margins
por: Yuan, Meng, et al.
Publicado: (2020)

PLNR≤20% may be a benefit from PORT for patients with IIIA-N2 NSCLC: a large population-based study
por: Shang, Xiaoling, et al.
Publicado: (2018)

Risk factors of brain metastases in completely resected pathological stage IIIA-N2 non-small cell lung cancer
por: Ding, Xiao, et al.
Publicado: (2012)

Selection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapy
por: Hui, Zhouguang, et al.
Publicado: (2015)

A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC
por: Crandall, John P., et al.
Publicado: (2017)

Segmentectomy or Wedge Resection in Stage IA Lung Squamous Cell Carcinoma and Adenocarcinoma?
por: Li, Guoshu, et al.
Publicado: (2021)

Prognostic Impact of Single and Multiple Descriptors in Pathologically Staged T3N0M0 NSCLC
por: Komiya, Takefumi, et al.
Publicado: (2020)

Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression
por: Chen, Zhiwei, et al.
Publicado: (2017)

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
por: Chen, Ping, et al.
Publicado: (2022)

Impact of Type 2 Diabetes Mellitus on the Prognosis of Non-Small Cell Lung Cancer
por: Lu, You, et al.
Publicado: (2022)

The diagnostic value of metagenomic next⁃generation sequencing in infectious diseases
por: Duan, Hongxia, et al.
Publicado: (2021)

The Prognosis According to Patterns of Mediastinal Lymph Node Metastasis in Pathologic Stage IIIA/N2 Non-Small Cell Lung Cancer
por: Kim, Do Wan, et al.
Publicado: (2014)

Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
por: Brazel, Danielle, et al.
Publicado: (2022)

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC
por: Lemmon, Christopher A., et al.
Publicado: (2022)

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
por: Zhong, Wen-Zhao, et al.
Publicado: (2021)

Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer
por: Montemuiño Muñiz, Sara, et al.
Publicado: (2021)

Structure of sulfamidase provides insight into the molecular pathology of mucopolysaccharidosis IIIA
por: Sidhu, Navdeep S., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ta9mopmvhi0hc3ia88phm41uc0